newsfilter
← Latest News
Business Wire·

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors

IM-1617 is a potential first-in-class solid tumor antibody-drug conjugate (ADC) that incorporates HC74, Immunome's proprietary topoisomerase I (TOP1) inhibitor payload Immunome ADC pipeline momentum anticipated to